Amgen drops early-stage obesity drug candidate AMG-513

Amgen announced it is discontinuing its early-stage obesity candidate AMG-513. The program was in Phase 1, but the company provided no details about the study or the reasons for the halt.

A spokesperson told Endpoints News that the decision was made internally and declined to elaborate further. No data from the trial have been released.

The move underscores the difficulty of advancing obesity therapies, a field that has seen both high expectations and frequent setbacks. Amgen’s pipeline will now focus on its remaining projects.